European Leukemia Trial Registry
Trial: TOWER

More Details
Title Phase 3 Trial of Blinatumomab vs Investigator's Choice of Chemotherapy in Patients With Relapsed or Refractory ALL
Scientific Title A Phase 3, Randomized, Open Label Study Investigating the Efficacy of the BiTE Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (TOWER Study)
Short Title TOWER
Trialgroup NN
Type of Trial multicentric, randomized, prospective, open-label
Disease Acute lymphoblastic leukemia(ALL) B-Precursor ALL
Age >= 18 years
Status Closed
Start of Recruitment 20.12.2013
Contactperson

Scientific Contact
Topp, Prof. Dr. med., Max
Tel: +49 (0)931 201 70490
Fax: +49 (0)931 201 70841
Email: topp_m@klinik.uni-wuerzburg.de

Scientific Contact
Gökbuget, Dr. med., Nicola
Tel: +49 (0)69 6301-6366
Fax: +49 (0)69 6301- 7463
Email: goekbuget@em.uni-frankfurt.de

Shortprotocol Shortprotocol
created 15.04.2014 Johannes Kraus
changed 03.05.2018 Student Studienregister
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org